DSMB hits pause on Voy­ager's Neu­ro­crine-part­nered Parkin­son's gene ther­a­py

Voy­ager Ther­a­peu­tics’ clin­i­cal plans have hit an­oth­er snag.

The Cam­bridge biotech dis­closed in their third quar­ter earn­ings Mon­day that the da­ta safe­ty and mon­i­tor­ing board …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER